Paris – A new era in HIV prevention is dawning in France with the arrival of cabotegravir, an injectable long-acting preventative treatment. Approved via a government decree on February 26, 2026, this medication offers a significant advancement over existing daily oral PrEP (pre-exposure prophylaxis) options, particularly for individuals who struggle with adherence to a pill-based regimen. The French government will fully cover the cost of cabotegravir, recognizing its “irreplaceable and particularly costly” nature, as outlined in the official decree published in the Journal officiel.
For years, the medical community and advocacy groups have anticipated the availability of this innovative treatment. Cabotegravir, marketed as Apretude by ViiV Healthcare – a subsidiary of GSK – is administered as an injection every two months, dramatically reducing the frequency of medication required compared to daily oral PrEP. This increased convenience is expected to improve adherence and, reduce new HIV infections. The World Health Organization (WHO) first recommended cabotegravir for PrEP in 2022, recognizing its potential to significantly impact global HIV prevention efforts. WHO’s recommendation highlighted the importance of offering diverse prevention options tailored to individual needs.
Currently, PrEP in France, and globally, relies heavily on daily oral medications. While effective, this approach presents challenges. Consistent adherence is crucial for PrEP to function, and missing doses can compromise its protective effect. The logistical and psychological burden of taking a daily pill can also lead to discontinuation of treatment. Cabotegravir addresses these issues by providing a discreet and less frequent dosing schedule, potentially reaching individuals who might not otherwise engage with PrEP. According to UNAIDS, approximately 1.3 million people gained access to PrEP in 2022, but significant gaps remain in reaching those most at risk.
A Long-Awaited Approval and Cost Considerations
The authorization of cabotegravir in France follows a nearly two-year evaluation process by the Haute Autorité de Santé (HAS), the French health authority. While the HAS initially deemed the improvement offered by cabotegravir as “moderate” in terms of medical benefit, the recent government decree underscores its commitment to providing access to this innovative preventative measure. The delay in implementation stemmed from negotiations regarding the drug’s price between health authorities and ViiV Healthcare. While the official list price for a dose of Apretude exceeds €1,000, the actual reimbursement rate by the French national health insurance system remains confidential.
Despite the enthusiasm surrounding cabotegravir, concerns remain regarding affordability and access to necessary testing. The French association Aides has voiced concerns about the cost of the mandatory HIV viral load test required before initiating injectable PrEP. Currently, this test is not fully covered by insurance, potentially creating a financial barrier for some individuals. Solenn Bazin, advocacy and prevention officer at Aides, emphasized that a “residual cost” may be incurred by the patient, potentially covered by supplemental health insurance (mutuelle).
Eligibility and Safety Considerations
The HAS has issued specific recommendations regarding the eligibility for cabotegravir. Notably, the treatment is not recommended for women of childbearing potential due to a “potential risk of fetal malformation.” This precaution is based on available safety data and reflects a conservative approach to risk management. The HAS guidelines also stipulate that individuals must have a negative HIV test result before starting cabotegravir to ensure they are not already infected.
The development of cabotegravir represents a significant milestone in HIV prevention research. The drug works by providing a high concentration of the antiretroviral medication in the bloodstream, offering protection against HIV infection even if exposure occurs. Clinical trials have demonstrated the efficacy of cabotegravir in reducing the risk of HIV acquisition among men who have sex with men and transgender women. The landmark HPTN 083 and HPTN 084 studies, published in the New England Journal of Medicine, showed that cabotegravir was significantly more effective than daily oral PrEP in preventing HIV infection. The HPTN 083 study, for example, demonstrated a 89% reduction in HIV incidence among participants receiving cabotegravir compared to those receiving a placebo.
Impact on Public Health and Future Directions
The introduction of cabotegravir is expected to have a positive impact on public health efforts to combat the HIV epidemic in France. By offering a more convenient and discreet prevention option, it has the potential to reach individuals who may not have previously considered or been able to adhere to daily oral PrEP. This is particularly important for key populations at higher risk of HIV infection, including men who have sex with men, transgender individuals, and people who engage in high-risk behaviors. According to data from Santé publique France, approximately 6,700 new HIV diagnoses were reported in France in 2022, highlighting the ongoing necessitate for effective prevention strategies.
Although, successful implementation of cabotegravir will require addressing several challenges. Ensuring equitable access to the drug, particularly for marginalized communities, is paramount. Healthcare providers will need to be trained on the proper administration and monitoring of cabotegravir, and public awareness campaigns will be crucial to educate individuals about this new prevention option. Continued research is also needed to assess the long-term efficacy and safety of cabotegravir, as well as to explore its potential use in combination with other prevention strategies. The development of long-acting injectable PrEP represents a significant step forward in the fight against HIV, but it is not a silver bullet. A comprehensive approach that includes education, testing, treatment, and prevention remains essential to achieving the goal of ending the HIV epidemic.
Key Takeaways
- New HIV Prevention Option: Cabotegravir, an injectable long-acting PrEP, is now available in France, offering a convenient alternative to daily pills.
- Government Funding: The French government will fully cover the cost of cabotegravir, recognizing its importance in HIV prevention.
- Eligibility Restrictions: The treatment is not recommended for women of childbearing potential due to potential fetal risks.
- Access Concerns: The cost of the required HIV viral load test remains a potential barrier to access for some individuals.
- Clinical Trial Success: Clinical trials have demonstrated cabotegravir’s superior efficacy compared to daily oral PrEP in reducing HIV infection risk.
Looking ahead, the French health authorities will continue to monitor the implementation of cabotegravir and assess its impact on HIV incidence. Further updates on reimbursement policies and eligibility criteria are expected in the coming months. Individuals interested in learning more about cabotegravir and PrEP are encouraged to consult with their healthcare provider or visit the website of Santé publique France. The availability of this innovative treatment marks a pivotal moment in the ongoing effort to protect public health and prevent the spread of HIV.